MX380301B - Prevención o tratamiento de enfermedades urinarias o gotosas. - Google Patents
Prevención o tratamiento de enfermedades urinarias o gotosas.Info
- Publication number
- MX380301B MX380301B MX2017009853A MX2017009853A MX380301B MX 380301 B MX380301 B MX 380301B MX 2017009853 A MX2017009853 A MX 2017009853A MX 2017009853 A MX2017009853 A MX 2017009853A MX 380301 B MX380301 B MX 380301B
- Authority
- MX
- Mexico
- Prior art keywords
- uric acid
- gout
- prevention
- treatment
- alkyl
- Prior art date
Links
- 201000005569 Gout Diseases 0.000 title abstract 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract 3
- 229940116269 uric acid Drugs 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010046337 Urate nephropathy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048096 | 2015-01-30 | ||
| CN201510080714 | 2015-02-13 | ||
| CN201510079809 | 2015-02-13 | ||
| CN201510216089 | 2015-04-30 | ||
| PCT/CN2016/000061 WO2016119570A1 (zh) | 2015-01-30 | 2016-01-28 | 尿酸性或痛风性疾病的预防或治疗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009853A MX2017009853A (es) | 2017-11-01 |
| MX380301B true MX380301B (es) | 2025-03-12 |
Family
ID=56542370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009853A MX380301B (es) | 2015-01-30 | 2016-01-28 | Prevención o tratamiento de enfermedades urinarias o gotosas. |
Country Status (26)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12566174B2 (en) | 2017-05-11 | 2026-03-03 | The Research Foundation For The State University Of New York | Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid |
| AU2024229006A1 (en) | 2023-02-27 | 2025-09-18 | Shanton Pharma Pte. Ltd. | Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor |
| CN116650490B (zh) * | 2023-06-07 | 2025-05-20 | 中国人民解放军海军军医大学 | 化合物mt-1207在降低尿酸方面的应用 |
| EP4497439A1 (en) * | 2023-07-28 | 2025-01-29 | Universitat de les Illes Balears | Compounds for the treatment or prevention of gout |
| TWI902254B (zh) * | 2024-05-16 | 2025-10-21 | 新加坡商珊頓醫藥科技新加坡公司 | 化合物8-氯-3-戊基-3,7-二氫-1h-嘌呤-2,6-二酮的晶型及其製備方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| WO1993016699A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| CA2556073C (en) | 2004-02-14 | 2012-01-10 | Smithkline Beecham Corporation | 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators |
| AR061626A1 (es) * | 2006-06-23 | 2008-09-10 | Incyte Corp | Derivados de purinona como agonistas de hm74a |
| CN101479273B (zh) | 2006-06-23 | 2011-11-30 | 英赛特股份有限公司 | 作为hm74a激动剂的嘌呤酮衍生物 |
| WO2010071865A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| US20110136835A1 (en) * | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
-
2016
- 2016-01-28 PT PT167426329T patent/PT3251675T/pt unknown
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/ko active Active
- 2016-01-28 HR HRP20211007TT patent/HRP20211007T1/hr unknown
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 PL PL16742632T patent/PL3251675T3/pl unknown
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/hu unknown
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 MX MX2017009853A patent/MX380301B/es unknown
- 2016-01-28 CA CA2973746A patent/CA2973746C/en active Active
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/pt not_active Application Discontinuation
- 2016-01-28 MA MA41431A patent/MA41431B1/fr unknown
- 2016-01-28 SM SM20210359T patent/SMT202100359T1/it unknown
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/zh not_active Ceased
- 2016-01-28 ES ES16742632T patent/ES2881872T3/es active Active
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/en active Active
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/da active
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/lt unknown
- 2016-01-28 EA EA201791714A patent/EA034139B1/ru unknown
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/ja active Active
- 2016-01-28 SI SI201631264T patent/SI3251675T1/sl unknown
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/zh active Active
- 2016-01-29 TW TW105102935A patent/TWI680761B/zh active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| PH12016501355A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| PH12016502081A1 (en) | Compounds for treating spinal muscular atrophy | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| MX2020011652A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| MX375925B (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| TN2015000386A1 (en) | Formulations of organic compounds | |
| CY1124383T1 (el) | Προληψη ή αγωγη παθησης ουρικου οξεος ή ποδαγρας | |
| NZ780408A (en) | Human plasma kallikrein inhibitors |